🇺🇸 FDA
Patent

US 10172789

Compositions for transdermal delivery of mTOR inhibitors

granted A61KA61K31/436A61K47/10

Quick answer

US patent 10172789 (Compositions for transdermal delivery of mTOR inhibitors) held by PALVELLA THERAPEUTICS, INC. expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PALVELLA THERAPEUTICS, INC.
Grant date
Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K31/436, A61K47/10, A61K47/12, A61K47/32